GU Cancer Clinical Trials

DISCLAIMER: All content found on cua.org is provided for information and education purposes. The medical information and clinical trials information is not intended to substitute for the advice of a physician, nor is it intended to provide legal advice. You should always consult your doctor for specific information on personal health matters, or other relevant professionals to ensure that your own circumstances are considered.

The CUA is not responsible in any manner for direct, indirect, special or consequential damages caused and/or arising from your use of cua.org.

Subspecialty
Prostate | BC | Recruiting
PROTRACT
PROstate Cancer Treatment Optimization Via Analysis of Circulating Tumour DNA (PROTRACT)
Dr. Kim N. Chi
Start Date: October 7, 2020

NCT #: NCT04015622

SPONSOR: British Columbia Cancer Agency

INFO: https://www.clinicaltrials.gov/ct2/show/NCT05328505

CONTACT: 

1. Dr. Kim Chi (Vancouver) 6048776000 ext 672734 - kchi@bccancer.bc.ca                                                                       
2. Dr. Joanna Vergidis (Victoria) 2505195572 - Jvergidis@bccancer.bc.ca                                                                
3. Dr. Daygen Finch (Kelowna). 2507123900 - DFinch-02@bccancer.bc.ca                                                        
4. Dr. Krista Noonan (Surrey) 6049304064 - KNoonan2@bccancer.bc.ca

Other Canadian Centres:

1. BC Cancer - Vancouver Centre,                                                                 
2. BC Cancer - Victoria Centre                                                                       
3. BC Cancer - Kelowna (Sindi Ahluwalia Hawkins Centre)                         
4. BC Cancer - Surrey Centre

Renal | AB, ON, QC | Recruiting
OC-001
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
Oscellaris Pharma, Inc.
Start Date: October 6, 2020

NCT #: NCT04260802

SPONSOR: Ocellaris Pharma, Inc.

INFO: https://clinicaltrials.gov/ct2/show/NCT04260802?recrs=abf&cond=Renal+Cell+Carcinoma&cntry=CA&draw=2&rank=20

CONTACT:

317-651-7036

OTHER CANADIAN CENTRES: 

Cross Cancer Institute (Edmonton): 780-432-8248
Ottawa Hospital Cancer Centre (OHRI) Ottawa 613-737-7700 x 70185                  
Princess Margaret Hospital (Toronto): 416-946-2818                                    
Jewish General Hospital (Montreal): 514-340-8222 x 25981                                    
Centre hospitalier de l'Universite de Montreal (CHUM): 514-890-8000 x 30758

 

Renal | BC, ON | Recruiting
ELVCAP-001-01
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
Elevation Oncology
Start Date: September 29, 2020

NCT #: NCT04383210

SPONSOR: Elevation Oncology

INFO:   https://clinicaltrials.gov/ct2/show/NCT04383210?recrs=abf&cond=Renal+Cell+Carcinoma&cntry=CA&draw=2&rank=30

CONTACT:  clinical@elevationoncology.com

OTHER CANADIAN CENTRES: 

Willian Osler Health System (Brampton)                                                       
Dr. Parneet Cheema: 416-747-3400

BC Cancer (Vancouver)                                                                                      
Dr. Janessa Laskin: 604-877-6000
 

 

Bladder | ON, QC | Recruiting
ARRAY-067-102
Study of PF-07265807 in Participants With Metastatic Solid Tumors
Pfizer
Start Date: September 24, 2020

NCT #: NCT04458259

SPONSOR: Pfizer

INFO: https://clinicaltrials.gov/ct2/show/NCT04458259?recrs=abf&cond=Urothelial+Carcinoma&cntry=CA&draw=2&rank=13

CONTACT: 1-800-718-1021

OTHER CANADIAN CENTRES:

1. Juravinski Cancer Centre (Hamilton)
2. University Health Network (Toronto)
3. CHU de Quebec-Universite Laval - Hotel Dieu de Quebec
4. Centre intégré de cancérologie du CHU de Québec Université Laval

Renal | ON | Active, not recruiting
D9950C00001 
First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours
AstraZeneca
Start Date: August 18, 2020

NCT #: D9950C00001

SPONSOR: AstraZeneca

INFO:  https://clinicaltrials.gov/ct2/show/NCT04504669?recrs=abf&cond=Renal+Cell+Carcinoma&cntry=CA&draw=2&rank=29

CONTACT:  information.center@astrazeneca.com

OTHER CANADIAN CENTRES: Edmonton & Toronto

 

 

 

Prostate | QC | Active, not recruiting
CROSSBOW
Two TraCer PositROn EmiSSion Tomography ComBination for Efficacy EstimatiOn of Prostate Specific Membrane Antigen Radioligand Therapy in Patients With Metastatic Prostate Cancer
Dr. Stephan Probst
Start Date: July 31, 2020

NCT #: NCT04085991

SPONSOR: Sir Mortimer B. Davis - Jewish General Hospital

INFO: https://clinicaltrials.gov/ct2/show/NCT04085991

 

Prostate | ON | Recruiting
EARTH
2 Ablative RadioTherapy Treatments for Prostate Cancer
Dr. Andrew Loblaw
Start Date: July 29, 2020

NCT #: NCT04654338

SPONSOR: Sunnybrook Health Sciences Centre

INFO:  https://clinicaltrials.gov/ct2/show/NCT04654338

CONTACT:  416-480-6100 ext 85454

Bladder | AB, ON | Recruiting
BT8009-100
Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Solid Tumors Malignancies
Bicycle Tx Limited
Start Date: July 17, 2020

NCT #: NCT04561362

SPONSOR: BicycleTx Limited 

INFO: https://clinicaltrials.gov/ct2/show/NCT04561362?recrs=abf&cond=Urothelial+Carcinoma&cntry=CA&draw=2&rank=11

CONTACT:  617-945-8155

OTHER CANADIAN CENTRES:

1. CROSS CANCER Institute (Edmonton): 780-432-8762
2. Princess Margaret Cancer Centre (Toronto): 416-946-2000

Prostate | ON | Recruiting
BL13F
Electronic 'Real-Time' Patient Self-Reporting of Immunotherapy Symptomatic Adverse Events using the SYMPTOM-IQ Tool on the uMotif Mobile Health Application (APP): A Prospective Feasibility Sub-Study of BL13 [e-PRISM]
Dr. Doris Howell (UHN)
Start Date: July 15, 2020

CONTACT:

(416) 946-4501 Ext. 3419

Renal | ON | Recruiting
BL13F
Electronic 'Real-Time' Patient Self-Reporting of Immunotherapy Symptomatic Adverse Events using the SYMPTOM-IQ Tool on the uMotif Mobile Health Application (APP): A Prospective Feasibility Sub-Study of BL13 [e-PRISM].
Dr. Doris Howell (UHN) - Toronto
Start Date: July 15, 2020

The Canadian Urological Association (CUA) does not provide professional medical advice, diagnosis or treatment and cannot respond to requests for direct feedback, specific patient information or physician referrals. You should first always seek the advice of your urologist, physician and other qualified health provider with any questions regarding your medical condition. The contents of the CUA Website such as text, graphics, images, and other content are for informational purposes only. The content/information is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on the CUA website.

For comments or information, email Corporate.office@cua.org

Privacy Policy